Easydiet S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Easydiet S.R.L. in Bucharest, research in cardiovascular diseases focuses on major conditions such as atherosclerotic cardiovascular disease, coronary heart disease, and broader cardiovascular disease. These studies are designed to test new treatment options and assess whether they can better reduce heart-related events and improve long-term outcomes.
- Evaluating therapies aimed at lowering the risk of heart attack, stroke, and other major cardiovascular events
- Studying treatments for people with atherosclerotic cardiovascular disease and elevated cardiovascular risk
- Assessing approaches that may improve prevention of first major cardiovascular events
This work also includes patients with chronic kidney disease and elevated lipoprotein(a), reflecting a strong focus on prevention, risk reduction, and better cardiovascular care.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases at this site center on type 2 diabetes, obesity, and overweight. The studies explore whether newer therapies can improve blood sugar control, support weight loss, and address related metabolic health concerns in adults living with these conditions.
- Testing treatments for type 2 diabetes with inadequate glycemic control
- Evaluating therapies for obesity and overweight in people with metabolic disease
- Investigating options that may improve both diabetes management and weight-related outcomes
Research at the Diabetes, Nutrition and Metabolic Disease Department includes studies that combine metabolic and cardiovascular goals, showing interest in therapies that may help patients with overlapping risk factors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Eli Lilly & Co.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Easydiet S.R.L.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-Pyran-4-Yl)-2-((S)-3-(3-(4-Fluoro-1-Methyl-1H-Indazol-5-Yl)-2-Oxo-2,3-Dihydro-1H-Imidazol-1-Yl)-2-(4-Fluoro-3,5-Dimethylphenyl)-4-Methyl-4,5,6,7-Tetrahydro-2H-Pyrazolo[4,3-C]Pyridine-5-Carbonyl)-1H-Indol-1-Yl)-2-Methylcyclopropyl)-5-Oxo-1,2,4-Oxadiazol-4-Ide Hemicalcium | 1 | Unknown | 2024-02-23 | 2024-02-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.